Prothena

PRTAPhase 3

Founded 2012prothena.com

Prothena is a publicly traded biotech firm with a scientific legacy tracing back to Athena Neurosciences (founded 1986), focusing on the biology of misfolded proteins. It has built a diverse pipeline of investigational therapies, including partnered programs with Roche (prasinezumab for Parkinson's) and Bristol Myers Squibb (PRX005). The company's strategy integrates internal discovery with strategic collaborations to advance transformative medicines for devastating neurological and amyloid disorders.

Market Cap

$471.0M

Founded

2012

Focus

AntibodiesBiologics

PRTA · Stock Price

USD 8.7528.20 (-76.32%)

Historical price data

AI Company Overview

Technology Platform

Antibody-based therapeutic platform targeting misfolded proteins and protein dysregulation, with expertise in designing antibodies against conformational epitopes on pathogenic proteins involved in neurodegenerative and amyloid diseases.

Pipeline Snapshot

10 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
Birtamimab + Standard of Care Chemotherapy	Light Chain (AL) Amyloidosis	Phase 3
NEOD001	Primary Systemic (AL) Amyloidosis	Phase 3
NEOD001	AL Amyloidosis	Phase 2
NEOD001 + Placebo	AL Amyloidosis	Phase 2
NEOD001	AL Amyloidosis	Phase 2

Funding History

Total raised: $255M

PIPE$175MEcoR1 CapitalDec 15, 2021

IPO$80MUndisclosedDec 7, 2012

Opportunities

Prothena has significant growth opportunities through clinical success in its pipeline targeting large, underserved markets like Parkinson's and Alzheimer's disease.

Its partnerships with Roche and Bristol Myers Squibb provide validation, non-dilutive funding, and commercial expertise.

The company can also leverage its protein misfolding platform to discover and develop new candidates for other neurodegenerative and amyloid disorders.

Risk Factors

Key risks include clinical trial failures for lead assets, intense competition in core therapeutic areas, regulatory hurdles for novel mechanisms, dependence on partners for major programs, and the need to manage financial runway as a pre-revenue company.

The high scientific and development complexity of targeting protein misfolding in the brain adds significant technical risk.

Competitive Landscape

Prothena faces competition from large pharma and biotech firms across all its focus areas. In Parkinson's, it competes with other alpha-synuclein programs; in ATTR amyloidosis, with approved TTR stabilizers and gene-silencing therapies; and in Alzheimer's, with dominant anti-amyloid players and other anti-tau developers. Its differentiation is its specialized expertise in conformational protein targets and a balanced pipeline of partnered and wholly-owned assets.

Publications

Patents

Pipeline